• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

应用国际 IgA 肾病预测工具于活检后一至两年。

Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy.

机构信息

Division of Nephrology, University of British Columbia, Vancouver, British Columbia, Canada; BC Renal, Vancouver, British Columbia, Canada.

Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy.

出版信息

Kidney Int. 2022 Jul;102(1):160-172. doi: 10.1016/j.kint.2022.02.042. Epub 2022 Apr 29.

DOI:10.1016/j.kint.2022.02.042
PMID:35490842
Abstract

The International IgA Nephropathy (IgAN) Prediction Tool is the preferred method in the 2021 KDIGO guidelines to predict, at the time of kidney biopsy, the risk of a 50% drop in estimated glomerular filtration rate or kidney failure. However, it is not known if the Prediction Tool can be accurately applied after a period of observation post-biopsy. Using an international multi-ethnic derivation cohort of 2,507 adults with IgAN, we updated the Prediction Tool for use one year after biopsy, and externally validated this in a cohort of 722 adults. The original Prediction Tool applied at one-year without modification had a coefficient of variation (R) of 55% and 54% and four-year concordance (C statistic) of 0.82 but poor calibration with under-prediction of risk (integrated calibration index (ICI) 1.54 and 2.11, with and without race, respectively). Our updated Prediction Tool had a better model fit with higher R (61% and 60%), significant increase in four-year C-statistic (0.87 and 0.86) and better four-year calibration with lower ICI (0.75 and 0.35). On external validation, the updated Prediction Tool had similar R (60% and 58%) and four-year C-statistics (both 0.85) compared to the derivation analysis, with excellent four-year calibration (ICI 0.62 and 0.56). This updated Prediction Tool had similar prediction performance when used two years after biopsy. Thus, the original Prediction Tool should be used only at the time of biopsy whereas our updated Prediction Tool can be used for risk stratification one or two years post-biopsy.

摘要

国际 IgA 肾病(IgAN)预测工具是 2021 年 KDIGO 指南中首选的方法,用于在肾活检时预测肾小球滤过率下降 50%或肾功能衰竭的风险。然而,尚不清楚该预测工具在活检后观察一段时间后是否可以准确应用。使用一个国际多民族衍生队列的 2507 例 IgAN 成人患者,我们更新了活检后一年使用的预测工具,并在 722 例成人队列中进行了外部验证。原始预测工具在未经修改的情况下应用于一年时,变异系数(R)为 55%和 54%,四年一致性(C 统计量)为 0.82,但校准效果不佳,风险预测偏低(综合校准指数(ICI)分别为 1.54 和 2.11,包括和不包括种族)。我们的更新预测工具具有更好的模型拟合度,R 值更高(61%和 60%),四年 C 统计量显著增加(0.87 和 0.86),四年校准效果更好,ICI 更低(0.75 和 0.35)。外部验证时,更新后的预测工具与衍生分析相比,R 值(60%和 58%)和四年 C 统计量(均为 0.85)相似,四年校准效果极佳(ICI 分别为 0.62 和 0.56)。更新后的预测工具在活检后两年使用时具有相似的预测性能。因此,原始预测工具仅应在活检时使用,而我们的更新预测工具可在活检后一到两年用于风险分层。

相似文献

1
Application of the International IgA Nephropathy Prediction Tool one or two years post-biopsy.应用国际 IgA 肾病预测工具于活检后一至两年。
Kidney Int. 2022 Jul;102(1):160-172. doi: 10.1016/j.kint.2022.02.042. Epub 2022 Apr 29.
2
Application of the updated International IgA Nephropathy Prediction Tool in children one or two years post-biopsy.更新后的国际 IgA 肾病预测工具在活检后一至两年的儿童中的应用。
Kidney Int. 2024 Nov;106(5):913-927. doi: 10.1016/j.kint.2024.07.012. Epub 2024 Jul 31.
3
External Validation of the International IgA Nephropathy Prediction Tool.国际 IgA 肾病预测工具的外部验证。
Clin J Am Soc Nephrol. 2020 Aug 7;15(8):1112-1120. doi: 10.2215/CJN.16021219. Epub 2020 Jul 2.
4
Validation of two IgA nephropathy risk-prediction tools using a cohort with a long follow-up.验证两种 IgA 肾病风险预测工具在长期随访队列中的应用。
Nephrol Dial Transplant. 2023 May 4;38(5):1183-1191. doi: 10.1093/ndt/gfac225.
5
Updating the International IgA Nephropathy Prediction Tool for use in children.更新国际 IgA 肾病预测工具,以用于儿童。
Kidney Int. 2021 Jun;99(6):1439-1450. doi: 10.1016/j.kint.2020.10.033. Epub 2020 Nov 18.
6
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.评估 IgA 肾病的新型国际风险预测工具。
JAMA Intern Med. 2019 Jul 1;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600.
7
External Validation of the International Prognosis Prediction Model of IgA Nephropathy.IgA 肾病国际预后预测模型的外部验证。
Ren Fail. 2024 Dec;46(1):2313174. doi: 10.1080/0886022X.2024.2313174. Epub 2024 Feb 12.
8
External validation of the pediatric International IgA Nephropathy Prediction Tool in a central China cohort.中国中部队列中儿科国际 IgA 肾病预测工具的外部验证。
Clin Exp Nephrol. 2024 Jan;28(1):59-66. doi: 10.1007/s10157-023-02402-5. Epub 2023 Sep 15.
9
Urinary Matrix Metalloproteinase 7 and Prediction of IgA Nephropathy Progression.尿基质金属蛋白酶 7与 IgA 肾病进展的预测。
Am J Kidney Dis. 2020 Mar;75(3):384-393. doi: 10.1053/j.ajkd.2019.07.018. Epub 2019 Oct 9.
10
Validation of the International IgA Nephropathy Prediction Tool in the Greek Registry of IgA Nephropathy.国际IgA肾病预测工具在希腊IgA肾病登记处的验证
Front Med (Lausanne). 2022 Feb 15;9:778464. doi: 10.3389/fmed.2022.778464. eCollection 2022.

引用本文的文献

1
Effect of time-weighted average 25(OH)D on the occurrence of major adverse kidney events in IgA nephropathy-from a 10-year population-based cohort study.时间加权平均25(OH)D对IgA肾病主要不良肾脏事件发生的影响——来自一项基于人群的10年队列研究
Front Nutr. 2025 Aug 1;12:1576488. doi: 10.3389/fnut.2025.1576488. eCollection 2025.
2
Validation of 2 Prognostic Models to Predict Renal Allograft Outcome After IgA Nephropathy Recurrence.两种预测IgA肾病复发后肾移植预后模型的验证
Kidney Int Rep. 2025 Apr 21;10(7):2323-2333. doi: 10.1016/j.ekir.2025.04.028. eCollection 2025 Jul.
3
Development and validation of personalized risk prediction models for patients with IgA nephropathy: a nationwide multicenter cohort study.
IgA肾病患者个性化风险预测模型的开发与验证:一项全国多中心队列研究
J Nephrol. 2025 Jul 11. doi: 10.1007/s40620-025-02338-x.
4
Using the International IgA Nephropathy Prediction Tool to Enrich Clinical Trial Cohorts.使用国际IgA肾病预测工具来富集临床试验队列。
Kidney Int Rep. 2025 Jan 20;10(4):1283-1287. doi: 10.1016/j.ekir.2025.01.025. eCollection 2025 Apr.
5
Population-Level Risk Factors for Kidney Outcomes in IgA Nephropathy: The CURE-CKD Registry.IgA肾病肾脏结局的人群水平风险因素:CURE-CKD注册研究
Kidney Med. 2025 Feb 13;7(4):100981. doi: 10.1016/j.xkme.2025.100981. eCollection 2025 Apr.
6
Emerging Biochemical and Immunologic Mechanisms in the Pathogenesis of IgA Nephropathy.IgA肾病发病机制中的新兴生化和免疫机制
Semin Nephrol. 2024 Sep;44(5):151565. doi: 10.1016/j.semnephrol.2025.151565. Epub 2025 Mar 13.
7
Risk-directed management of chronic kidney disease.慢性肾脏病的风险导向管理
Nat Rev Nephrol. 2025 May;21(5):287-298. doi: 10.1038/s41581-025-00931-8. Epub 2025 Jan 30.
8
Lifetime progression of IgA nephropathy: a retrospective cohort study with extended long-term follow-up.IgA肾病的终身进展:一项具有长期随访的回顾性队列研究。
BMC Nephrol. 2025 Jan 21;26(1):32. doi: 10.1186/s12882-025-03958-y.
9
Systematic review of the application of the Kidney Failure Risk Equation and Oxford classification in estimating prognosis in IgA Nephropathy.关于肾衰竭风险方程及牛津分类法在评估IgA肾病预后中应用的系统评价
Syst Rev. 2025 Jan 16;14(1):16. doi: 10.1186/s13643-024-02739-2.
10
Towards Risk Stratification in Clinical Care for IgA Nephropathy: Genetic Risk Scores: Comments on the Study "Clinical Application of Polygenic Risk Score in IgA Nephropathy".IgA肾病临床护理中的风险分层:遗传风险评分:对“多基因风险评分在IgA肾病中的临床应用”研究的评论
Phenomics. 2024 Nov 12;4(5):527-530. doi: 10.1007/s43657-024-00184-8. eCollection 2024 Oct.